Who is sponsoring NCT05222243?

NCT05222243 is sponsored by Mansoura University.

What drugs are being tested in NCT05222243?

Interventions in NCT05222243: Direct pulp capping with calcium hydroxide, Direct pulp capping with MTA, Direct pulp capping with Formocresol.

What condition does NCT05222243 study?

NCT05222243 studies Direct Pulp Capping in Primary Teeth.

Is NCT05222243 still recruiting?

NCT05222243 is currently completed. Last updated 3 February 2022.

Last reviewed 2022-02-03 · How we verify

NCT05222243

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DPC in Primary Molars.

Completed Phase 4 Last updated 3 February 2022

What this trial tests

Phase 4 trial testing Direct pulp capping with calcium hydroxide in Direct Pulp Capping in Primary Teeth in 60 participants. Completed in 1 December 2020.

Timeline

1 January 2019

Primary endpoint
3 August 2020

1 December 2020

Quick facts

Lead sponsor	Mansoura University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 January 2019
Primary completion	3 August 2020
Estimated completion	1 December 2020
Sites	1 location across Egypt

Drugs / interventions tested

Direct pulp capping with calcium hydroxide — full drug profile →
Direct pulp capping with MTA — full drug profile →
Direct pulp capping with Formocresol — full drug profile →

Conditions studied

Direct Pulp Capping in Primary Teeth — all drugs for Direct Pulp Capping in Primary Teeth →

Sponsor

Mansoura University

Who can join

Adults 4 to 8, any sex, with Direct Pulp Capping in Primary Teeth. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate clinical and radiographical outcomes of direct pulp capping using calcium hydroxide (CH), mineral trioxide aggregate (MTA), and premedicated direct pulp capping (PDPC) with formocresol (FC) in primary teeth.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Mansoura University trials

Trials by the same sponsor.

NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
NCT07534943 — Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Period · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05222243 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mansoura University
Last refreshed: 3 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05222243.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing